Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Trial Profile

Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ibrutinib
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Sep 2021 to 1 Jun 2021.
    • 06 Dec 2016 Results (n=12) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 24 Oct 2016 Planned number of patients changed from 48 to 72.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top